Summary & Overview
CPT 4142F: IBD Corticosteroid-Sparing Medication Prescription
CPT code 4142F identifies when a provider prescribes a corticosteroid-sparing medication, such as an immunomodulatory agent, to manage inflammatory bowel disease (IBD) while avoiding corticosteroid-related adverse effects. Nationally, this code captures a shift in IBD care toward long-term maintenance strategies that reduce steroid exposure, an important quality and safety consideration given the risks of prolonged corticosteroid use.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical intent, typical service setting, and how it is used in quality reporting and treatment documentation. The publication outlines common modifiers and notes areas where input data is not available, and it situates the code within clinical management of IBD rather than procedural billing.
This summary prepares clinicians, coding staff, and policy analysts to understand how CPT code 4142F is applied in ambulatory gastroenterology practices, what aspects of care it documents, and which payers commonly interact with claims using this code. Data not available in the input is explicitly noted where relevant in the full publication.
Billing Code Overview
CPT code 4142F documents that a provider prescribes a corticosteroid-sparing medication, such as an immunomodulatory drug, to treat inflammatory bowel disease (IBD) while minimizing the side effects associated with corticosteroids. This code reflects the clinical decision to employ steroid-sparing therapy as part of ongoing medical management for patients with IBD.
-
Service type: Prescription management / medication therapy for chronic inflammatory disease
-
Typical site of service: Ambulatory clinic or outpatient gastroenterology practice where IBD is managed
Clinical & Coding Specifications
Clinical Context
A typical patient is a 28–45-year-old adult diagnosed with moderate to severe inflammatory bowel disease (Crohn disease or ulcerative colitis) who requires long-term control of intestinal inflammation while minimizing corticosteroid exposure. The patient presents to a gastroenterology clinic for routine follow-up after an acute flare partially responsive to oral corticosteroids. The provider documents steroid dependence or steroid-related adverse effects (weight gain, hyperglycemia, osteoporosis risk) and elects to prescribe a corticosteroid-sparing immunomodulatory or biologic agent (for example azathioprine, 6-mercaptopurine, methotrexate, or an anti-TNF agent) to achieve and maintain remission.
Clinical workflow: the gastroenterologist evaluates disease activity through history, physical exam, laboratory tests (CBC, CMP, thiopurine methyltransferase or TPMT testing when indicated), and inflammatory markers (CRP, fecal calprotectin). The provider discusses medication options, documents rationale for steroid-sparing therapy in the chart, obtains baseline screening (hepatitis B/C, TB testing where applicable), prescribes the selected immunomodulator or biologic, and arranges infusion or injection training, prior authorization, and follow-up monitoring. Typical site of service is outpatient gastroenterology clinic or infusion center for parenteral biologics.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
52 | Reduced Services | Use when the service is partially reduced or not performed to the full extent, for example if medication initiation was planned but only counseling occurred. |